Navigation Links
Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
Date:1/6/2012

MADISON, N.J., Jan. 6, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the successful completion of its previously announced agreement with Lovelace Health System to acquire S.E.D. Medical Laboratories. Under the terms of the transaction, Quest Diagnostics has acquired the assets of S.E.D. Medical Laboratories and will manage in-patient labs for the four Lovelace hospitals, as well as serve Lovelace Health Plan members. Financial terms of the transaction were not disclosed.

Based in Albuquerque, New Mexico, S.E.D. Medical Laboratories is a nationally recognized full-service medical and federally certified drugs-of-abuse testing laboratory with a staff of 450. S.E.D. operates from a modern 50,000 square-foot facility with state-of-the-art equipment and cutting-edge technology. The acquisition includes the transfer of the main offices and lab on Office Boulevard near I-25 and Jefferson, nine Patient Service Centers in Albuquerque and Rio Rancho and six additional locations across New Mexico. 

About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: www.QuestDiagnostics.com.

Contacts:
Kathleen Valentine (Investors): 973-520-2900
Gary Samuels (Media): 973-520-2800

 


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Autism ... to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis and ... global Autism Spectrum Disorder market. The research answers the following ... marketed for Autism Spectrum Disorder and their clinical attributes? How are ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Country Club in Miami Beach to host its Swirl: Miami Wine Tasting Event ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association ... Annual Meeting. KLS is a longtime supporter of the event. , "We are ... Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid ... sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental Group ... for a dinner for two at the Cheesecake Factory. , Tickets are available ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a ... Mahon was named a 2017 Top Patient Rated Henderson Dentist by Find ... that recognizes local physicians and dentists who have earned high ratings and superior patient ...
Breaking Medicine News(10 mins):